ArticleCureus2025
Beyond the First Year of Intravitreal Faricimab for Diabetic Macular Oedema: A Single-Centre Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Four-Year Outcomes of Faricimab in Diabetic Macular Edema in the RHONE-X Extension Trial: A Podcast.Ophthalmology and therapy · 2026Review
- First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective To determine real-world clinical outcomes (including vision, anatomy and durability) of intravitreal faricimab (IVF) in year two (up to mean follow-up of 75 ± 15 weeks, range: 52-103 weeks) of treating diabetic macular oedema (DMO). Secondary objectives included assessing changes in diabetic retinopathy (DR) severity, the incidence of epiretinal proliferation (ERP)/epiretinal membrane (ERM), and safety. Methodology This is a single-centre retrospective observational study. Eligible eyes with ≥52 weeks follow-up, October 2022 to November 2024, were identified and categorised into naïve (no prior anti-vascular endothelial growth factor (anti-VEGF) agents) and switch (≥1 prior anti-VEGF). Descriptive statistics at week 52 (W52) and end of follow-up (EOFU) summarised mean BCVA and CFT change, mean IVF injections and frequency, DR severity change, epiretinal proliferation (ERP)/membrane (ERM) incidence, and safety. Results In total, 158 eyes (66 naïve, 92 switch) of 118 patients were identified, mean follow of 75 weeks. Mean W52 BCVA change was +3.6 (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.